JPMorgan analyst Jessica Fye raised the firm’s price target on Intra-Cellular to $75 from $65 and keeps an Overweight rating on the shares. The analyst believes the company’s first adjunctive depression pivotal trial is “reasonably de-risked” based on Caplytas track record in the clinic showing benefit on depressive episodes in multiple late-stage trials. The firm is using a 70% probability of success. Ahead of the trial readouts JPMorgan is putting Intra-Cellular on “Positive Catalyst Watch.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular CEO sells $2.27M in common stock
- Intra-Cellular initiated with Outperform on Caplyta growth at Baird
- Intra-Cellular initiated with an Outperform at Baird
- Intra-Cellular price target raised to $82 from $74 at BofA
- Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference